Gower Bob G's Form 4 filing
Ensysce Biosciences, Inc. (ENSC) · filed Mar 2, 2023
- Accession no.
- 0001493152-23-006553
- Filed
- Mar 2, 2023, 3:45 PM ET
- Trade date
- Feb 28-Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $182.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gower Bob GCIK 0001136466 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | Common Stock | PPurchaseAcquired | +109,300 | $0.4883 | +$53,371.19 | 862,395 | Direct | |
| Mar 1, 2023 | Common Stock | PPurchaseAcquired | +270,000 | $0.4777 | +$128,979 | 1,132,395 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.